Compare Stocks: VNRX, PHIO, BLRX, and GDTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$2.17 -2.3%	$2.59	$2.14 ▼ $4.14	$11.03M	1.61	15,110 shs	28,171 shs
GDTC CytoMed Therapeutics	$0.81 -8.8%	$0.89	$0.68 ▼ $3.68	$10.53M	0.06	19,392 shs	54,761 shs
PHIO Phio Pharmaceuticals	$0.92 -5.8%	$1.06	$0.81 ▼ $4.19	$11.37M	0.84	104,496 shs	45,472 shs
VNRX VolitionRX	$0.20 -3.9%	$0.39	$0.20 ▼ $10.31	$2.88M	1.17	3.37 million shs	771,695 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	-2.25%	-5.65%	-13.55%	-28.85%	-44.22%
GDTC CytoMed Therapeutics	-8.83%	-19.66%	+3.79%	-18.37%	-60.61%
PHIO Phio Pharmaceuticals	-5.80%	-6.96%	-10.49%	-10.49%	-58.09%
VNRX VolitionRX	-3.88%	-12.46%	-34.53%	-84.01%	-97.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$2.17 -2.3%	$2.59	$2.14 ▼ $4.14	$11.03M	1.61	15,110 shs	28,171 shs
GDTC CytoMed Therapeutics	$0.81 -8.8%	$0.89	$0.68 ▼ $3.68	$10.53M	0.06	19,392 shs	54,761 shs
PHIO Phio Pharmaceuticals	$0.92 -5.8%	$1.06	$0.81 ▼ $4.19	$11.37M	0.84	104,496 shs	45,472 shs
VNRX VolitionRX	$0.20 -3.9%	$0.39	$0.20 ▼ $10.31	$2.88M	1.17	3.37 million shs	771,695 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	-2.25%	-5.65%	-13.55%	-28.85%	-44.22%
GDTC CytoMed Therapeutics	-8.83%	-19.66%	+3.79%	-18.37%	-60.61%
PHIO Phio Pharmaceuticals	-5.80%	-6.96%	-10.49%	-10.49%	-58.09%
VNRX VolitionRX	-3.88%	-12.46%	-34.53%	-84.01%	-97.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLRX BioLineRx	1.00	Sell	N/A	N/A
GDTC CytoMed Therapeutics	2.00	Hold	$4.16	412.69% Upside
PHIO Phio Pharmaceuticals	2.00	Hold	$14.00	1,418.44% Upside
VNRX VolitionRX	2.40	Hold	$28.00	13,686.31% Upside

Current Analyst Ratings Breakdown

Latest VNRX, PHIO, BLRX, and GDTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	GDTC CytoMed Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/15/2026	GDTC CytoMed Therapeutics	Fundamental Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$4.16
8/26/2026	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	VNRX VolitionRX	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
7/17/2026	BLRX BioLineRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PHIO Phio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLRX BioLineRx	$1.18M	9.16	N/A	N/A	$5.36 per share	0.40
GDTC CytoMed Therapeutics	$250K	38.40	N/A	N/A	$0.45 per share	1.80
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$1.87 per share	N/A
VNRX VolitionRX	$1.73M	1.60	N/A	N/A	($5.30) per share	-0.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLRX BioLineRx	-$1.17M	-$1.69	N/A	N/A	N/A	-502.08%	-34.80%	-18.27%	11/23/2026 (Estimated)
GDTC CytoMed Therapeutics	-$3.10M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	11/13/2026 (Estimated)
PHIO Phio Pharmaceuticals	-$8.70M	-$1.29	N/A	N/A	N/A	N/A	-87.41%	-79.76%	11/12/2026 (Estimated)
VNRX VolitionRX	-$23.36M	-$0.56	N/A	N/A	N/A	-1,043.12%	N/A	-303.75%	11/12/2026 (Estimated)

Latest VNRX, PHIO, BLRX, and GDTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/30/2026	H1 2026	GDTC CytoMed Therapeutics	N/A	-$0.06	N/A	-$0.06	N/A	$0.06 million
8/28/2026	Q2 2026	BLRX BioLineRx	-$0.15	-$0.77	-$0.62	N/A	$0.50 million	$0.29 million
8/13/2026	Q2 2026	VNRX VolitionRX	-$0.5675	-$0.85	-$0.2825	-$0.85	$0.42 million	$0.40 million
8/6/2026	Q2 2026	PHIO Phio Pharmaceuticals	-$0.36	-$0.36	N/A	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
GDTC CytoMed Therapeutics	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLRX BioLineRx	0.13	1.20	1.04
GDTC CytoMed Therapeutics	0.07	2.64	N/A
PHIO Phio Pharmaceuticals	N/A	8.39	8.39
VNRX VolitionRX	N/A	0.30	0.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLRX BioLineRx	1.56%
GDTC CytoMed Therapeutics	0.04%
PHIO Phio Pharmaceuticals	57.31%
VNRX VolitionRX	8.09%

Insider Ownership

Company	Insider Ownership
BLRX BioLineRx	1.10%
GDTC CytoMed Therapeutics	N/A
PHIO Phio Pharmaceuticals	3.52%
VNRX VolitionRX	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLRX BioLineRx	24	4.98 million	4.92 million	Optionable
GDTC CytoMed Therapeutics	42	11.83 million	N/A	Not Optionable
PHIO Phio Pharmaceuticals	6	11.62 million	11.21 million	Not Optionable
VNRX VolitionRX	75	13.65 million	12.71 million	Not Optionable

VNRX, PHIO, BLRX, and GDTC Headlines

Recent News About These Companies

VolitionRx consensus price target decreased by 17.44% to $13.89

October 2, 2026 | msn.com

VolitionRx stock faces a data driven trading reset

September 22, 2026 | ad-hoc-news.deA

VolitionRx Limited stock edges higher as investors weigh recent results

September 18, 2026 | ad-hoc-news.deA

MissionIRNewsBreaks – VolitionRx (NYSE American: VNRX) Joins €6.3 Million French Government-Funded DETECSEPS Sepsis Project

September 17, 2026 | financialcontent.comF

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

September 17, 2026 | prnewswire.com

VolitionRx Participates in Launch of DETECSEPS Program in France

September 17, 2026 | prnewswire.com

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

September 14, 2026 | prnewswire.com

Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

September 10, 2026 | prnewswire.com

VolitionRX Earnings Call: Scientific Momentum Meets Cash Risks

August 26, 2026 | tipranks.com

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

August 26, 2026 | prnewswire.com

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

August 26, 2026 | prnewswire.com

Volition (VNRX) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

Volitionrx Ltd Stock Price History

August 20, 2026 | investing.com

VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript

August 14, 2026 | seekingalpha.com

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

August 13, 2026 | prnewswire.com

VolitionRx Limited (VNRX) Stock Major Holders - Yahoo Finance

August 13, 2026 | finance.yahoo.com

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

August 12, 2026 | prnewswire.com

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

August 11, 2026 | prnewswire.com

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

August 5, 2026 | prnewswire.com

Volition Advances Nu.Q® NETs Platform Towards Commercialization

July 30, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, PHIO, BLRX, and GDTC Company Descriptions

BioLineRx NASDAQ:BLRX

$2.20 -0.02 (-1.08%)

As of 10/12/2026 04:00 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

CytoMed Therapeutics NASDAQ:GDTC

$0.84 -0.06 (-6.18%)

As of 10/12/2026 04:00 PM Eastern

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

Phio Pharmaceuticals NASDAQ:PHIO

$0.92 -0.06 (-5.80%)

Closing price 10/12/2026 04:00 PM Eastern

Extended Trading

$0.98 +0.06 (+6.29%)

As of 10/12/2026 07:30 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

VolitionRX NYSEAMERICAN:VNRX

$0.20 -0.01 (-3.88%)

Closing price 10/12/2026 04:10 PM Eastern

Extended Trading

$0.20 +0.00 (+0.44%)

As of 10/12/2026 07:46 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNRX, PHIO, BLRX, and GDTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNRX, PHIO, BLRX, and GDTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNRX, PHIO, BLRX, and GDTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, PHIO, BLRX, and GDTC Company Descriptions

BioLineRx NASDAQ:BLRX

CytoMed Therapeutics NASDAQ:GDTC

Phio Pharmaceuticals NASDAQ:PHIO

VolitionRX NYSEAMERICAN:VNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNRX, PHIO, BLRX, and GDTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNRX, PHIO, BLRX, and GDTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNRX, PHIO, BLRX, and GDTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, PHIO, BLRX, and GDTC Company Descriptions

BioLineRx NASDAQ:BLRX

CytoMed Therapeutics NASDAQ:GDTC

Phio Pharmaceuticals NASDAQ:PHIO

VolitionRX NYSEAMERICAN:VNRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools